## Annex 1B. Sources of Cost-Effectiveness Analysis for Selected Infectious Disease Interventions


<table>
<thead>
<tr>
<th>Intervention</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Voluntary male circumcision</td>
<td>Fieno (2008); Kahn and others (2006); Kripke and others (2016); Njeumeli and others (2011)</td>
</tr>
<tr>
<td>Treat severe malaria with artesunate Africa &amp; SE Asia</td>
<td>Lubell (2011); Lubell and others (2009)</td>
</tr>
<tr>
<td>Preventive chemotherapy for onchocerciasis</td>
<td>Keating and others (2014); Turner and others (2014)</td>
</tr>
<tr>
<td>Add syphilis screen to HIV screen/treat, LIC</td>
<td>Schackman and others (2007)</td>
</tr>
<tr>
<td>Preventive chemotherapy, lymphatic filariasis</td>
<td>Stone and others (2016)</td>
</tr>
<tr>
<td>Screen/treat for syphilis LIC</td>
<td>Terris-Prestholt and others (2003); Kuznik and others (2013); Kahn and others (2014)</td>
</tr>
<tr>
<td>Treat smear positive TB with’ first line drugs LIC</td>
<td>Borgdorff and others (2002)</td>
</tr>
<tr>
<td>Detect &amp; treat visceral leishmanianias</td>
<td>Federici and others (2016)</td>
</tr>
<tr>
<td>Treat malaria with ACT (artemisinin combination therapy), Africa</td>
<td>Coleman and others (2004)</td>
</tr>
<tr>
<td>Preventive chemotherapy, schistosomiasis &amp; STH</td>
<td>Lo and others (2015); Turner and others (2014)</td>
</tr>
<tr>
<td>PMTCT Option B HIV vs no treatment, Africa</td>
<td>Orlando and others (2010);</td>
</tr>
<tr>
<td>Intermittent preventive treatment malaria in infants, Africa</td>
<td>Conteh and others (2010); Ross and others (2011)</td>
</tr>
<tr>
<td>Hepatitis B vaccination</td>
<td>Griffiths and others (2005); Kim and others (2007); Prakash (2003)</td>
</tr>
<tr>
<td>Preventive chemotherapy for trachoma</td>
<td>Baltussen and others (2012); Baltussen and others (2005)</td>
</tr>
<tr>
<td>Intermittent preventive treatment malaria in pregnancy, Africa</td>
<td>Mbonye and others (2008)</td>
</tr>
<tr>
<td>Detect and treat leprosy</td>
<td>Renne and others (2006)</td>
</tr>
<tr>
<td>Indoor residual spraying for malaria, Africa</td>
<td>Yukich and others (2007)</td>
</tr>
<tr>
<td>Comprehensive management malaria (spray, nets, treat, Africa)</td>
<td>Utzinger and others (2001)</td>
</tr>
<tr>
<td>Treat smear negative TB with first line drugs LIC</td>
<td>Borgdorff and others (2002)</td>
</tr>
<tr>
<td>Add Gene Xpert to smear to diagnose TB, LMIC</td>
<td>Vassall and others 2011</td>
</tr>
<tr>
<td>Supply insecticide-treated nets for malaria, Africa</td>
<td>Becker-Dreps and others (2009); Wiseman and others (2003); Hanson and others (2003)</td>
</tr>
<tr>
<td>Detect &amp; treat human African trypanosomiasis</td>
<td>Sutherland and others 2015</td>
</tr>
<tr>
<td>Home presumptive treatment malaria, Africa</td>
<td>Nonvignon and others (2012)</td>
</tr>
<tr>
<td>Add syphilis screen to HIV screen/treat, UMIC</td>
<td>Owusi-Edusei and others (2014)</td>
</tr>
<tr>
<td>Scale up ART to all infected, South Africa</td>
<td>Alistar and others (2014); Granich and others (2012)</td>
</tr>
<tr>
<td>Treat TB w’ second line drugs MIC</td>
<td>Fitzpatrick and others (2012)</td>
</tr>
<tr>
<td>Intervention</td>
<td>Sources</td>
</tr>
<tr>
<td>------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Screen/treat for syphilis UMIC</td>
<td>Hong and others (2010); Owusi-Edusei and others (2014)</td>
</tr>
<tr>
<td>Eradicate yaws (detect &amp; treat)</td>
<td>Fitzpatrick and others (2015); WHO (2015)</td>
</tr>
<tr>
<td>PMTCT Option A HIV vs no treatment, SE Asia</td>
<td>Hogan and others (2005)</td>
</tr>
<tr>
<td>BCC plus regulation, sex establishments LAC</td>
<td>Sweat and others (2006)</td>
</tr>
<tr>
<td>Vector control for dengue</td>
<td>Luz and others (2011); Suaya and others (2007)</td>
</tr>
<tr>
<td>Use Xpert to diagnose TB, MIC</td>
<td>Menzies and others (2012)</td>
</tr>
<tr>
<td>BCC alone, sex establishments, LAC</td>
<td>Sweat and others (2005)</td>
</tr>
<tr>
<td>Online sex education to prevent sexually transmitted infections, LAC</td>
<td>Chong and others (2013)</td>
</tr>
<tr>
<td>Vector control for dengue</td>
<td>Luz and others (2011); Suaya and others (2007)</td>
</tr>
<tr>
<td>Female condom S Af</td>
<td>Marseille and others (2008)</td>
</tr>
<tr>
<td>Use Xpert to diagnose TB, MIC</td>
<td>Menzies and others (2012)</td>
</tr>
<tr>
<td>PrEP during pregnancy + breastfeeding S Af</td>
<td>Price and others (2016)</td>
</tr>
<tr>
<td>Scale up ART to all infected lower-mid income Af</td>
<td>Marseille and others (2012)</td>
</tr>
<tr>
<td>PMTCT Option A (w' mass screen) vs no treatment, LAC</td>
<td>Aldridge and others (2009)</td>
</tr>
<tr>
<td>PrEP – Anti-retroviral therapy for non-infected partner, serodiscordant couples</td>
<td>Hallett and others (2011); Jewell and others (2015)</td>
</tr>
<tr>
<td>Hepatitis C treatment, UMICs</td>
<td>Chen and others (2016)</td>
</tr>
</tbody>
</table>

**Note:**

- **BCC** – behavior change communication
- **LAC** – Latin America and the Caribbean
- **LIC** - low income country
- **LMIC** - low and middle income country
- **Option A** – provide single-drug regimen to HIV-positive women during pregnancy and breastfeeding, to reduce the risk of transmission to their babies
- **Option B** – as for Option A, but using a two-drug regimen
- **Option B+** - As for Option B, but continued for life
- **PMTCT** – elimination of mother to child transmission (of HIV)
- **PrEP** – pre-exposure prophylaxis: antiretrovirals taken by non-infected individuals, to prevent infection with HIV
- **TB** – Tuberculosis
- **UMIC** – upper middle income country
References


doi:10.1371/journal.pmed.1001132.


Yukich, J., F. Tediosi and C. Lengeler. 2007. “Operations, costs and cost-effectiveness of five-insecticide-treated programs (Eritrea, Malawi, Tanzania, Togo, Senegal) and two indoor residual spraying programs (Kwa-Zulu-Natal, Mozambique).” Basel: Swiss Tropical Institute, final draft